Group 2D: Lobular Breast Cancer; Animal Models

Wednesday, Dec 14
2:00 pm – 3:30 pm Eastern Time (US/New York)

Poster #P3-08-10

Combining multiomics and histological assessment to identify patient derived xenograft models of invasive lobular carcinoma

Poster author Steffi Oesterreich, Ph.D. is also the scientist for this session

Poster #HER2-14:

HER-2 low status in early stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series

Mentor: Stephanie Walker, R.N.

Stephanie Walker was diagnosed in July 2015 with de novo MBC. A retired RN with close to 40 years of clinical practice and 3 years teaching in a Community College. Her experience has been pediatric and adult critical care working in level 1 trauma centers and critical access hospitals. The last 15 years of her nursing career were with Hospice care. She is a member of many organizations local and national based and a recipient of the Spirit to Impact award. She is also project lead on an initiative called BECOME (Black Experience of Clinical Trials and Opportunities of Meaningful Engagement), as part of the MBC Alliance. She is advocating for men and women in rural areas for equal access to quality healthcare, treatment modalities, and resources. She does not want anyone to feel alone, isolated, or defeated.

Twitter: @faceofstage4

Scientist: Steffi Oesterreich, Ph.D.

Dr Oesterreich’s area of interest is endocrine resistance and metastatic disease in breast cancer. Her lab studies mutations and epigenetic changes that lead to resistance to commonly used hormonal therapies that such Tamoxifen and Aromatase inhibitors. One focus area is the understanding of invasive lobular cancer, an understudied histological breast cancer subtype that affects 26,000-39,000 patients per year in the US alone. To reach the goal of translating findings into the clinic, she works in transdisciplinary teams, including medical oncologists, surgeons, biostatisticians, bioinformaticians and pathologists. All of these studies include many aspects of translational breast cancer research utilizing basic biochemistry, molecular and cell biology, cell lines, rodent models and clinical samples from retrospective cohort studies, and from clinical trials.

Twitter: @oesterreichs